1 unknown. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
Follow Intermediate-high Risk: new trials by email Literature Review of Intermediate-high Risk trials Research Report on Intermediate-high Risk
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism Sildenafil/apixaban, apixaban - Pulmonary Embolism, Intermediate-high Risk | Phase 1 | Unknown | Meshalkin Research Institute of Pathology of Circulation | 100 | 2016-10-01 | 2016-11-01 |
Cardiovascular Diseases (1) · Embolism (1) · Embolism and Thrombosis (1) · Lung Diseases (1) · Respiratory Tract Diseases (1) · Vascular Diseases (1)
Sildenafil Citrate (1) · apixaban (1)
Meshalkin Research Institute of Pathology of Circulation (1)
Russia (1)